Oral delivery of GLP-1 analogues by recombinant Lactococcus lactis restores pancreatic islet structure through intestinal mucosal absorption in diabetic mice | Synapse
March 3, 2026Open Access
Oral delivery of GLP-1 analogues by recombinant Lactococcus lactis restores pancreatic islet structure through intestinal mucosal absorption in diabetic mice
Puntos clave
Improved pancreatic islet structure was observed, indicating potential therapeutic benefits of GLP-1 analogues.
Specifically, the oral delivery of GLP-1 analogues using Lactococcus lactis positively affected diabetes management.
Analysis focused on the capacity of intestinal mucosal absorption to enhance therapeutic effects in a diabetic model.
This research highlights a promising new approach for diabetes treatment with oral formulations of GLP-1.